Skip to content

Released Feb 12, 2024, before the open

10-Q filed Feb 12, 2024, 43 days after period end · 0001764013-24-000026

Q3 2024 · 10-Q
Revenue—
Net Income-$51.42MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.36N/M vs Q3 2023N/M vs Q2 2024
Operating Cash Flowderived-$47,098,000N/M
Free Cash Flowderived-$47,229,000N/M

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2018
Net Income-$51.42M-$63.23M-$41.39M-$8.85M
EPS Diluted-$0.36-$0.49-$0.36-$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR